Is Loxo Oncology Inc (LOXO) A Good Stock To Buy?
"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing.
Loxo Oncology Inc. (LOXO)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $138.92 | 725 | $100,715.91 | 126,843 | 2018-12-13 | Filing | |
| $31.00 | 160,000 | $4,960,000.00 | 4,188,920 | 2017-01-10 | Filing | |
| $21.50 | 232,558 | $4,999,997.00 | 4,028,920 | 2016-05-17 | Filing | |
| $27.50 | 200 | $5,500.00 | 3,796,362 | 2015-12-11 | Filing | |
| $26.50 | 3,773 | $99,984.50 | 159,118 | 2015-11-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $140.16 | 541 | $75,826.56 | 13,700 | 2018-12-11 | Filing | |
| $139.23 | 500 | $69,615.00 | 14,241 | 2018-12-11 | Filing | |
| $137.73 | 500 | $68,865.00 | 14,741 | 2018-12-11 | Filing | |
| $137.09 | 1,759 | $241,141.31 | 15,241 | 2018-12-11 | Filing | |
| $135.92 | 800 | $108,736.00 | 17,000 | 2018-12-11 | Filing |
Institutional Investors' Holdings
News See All
Hedge Fund and Insider Trading News: Ken Griffin, Elliott Management Corp., AutoNation, Inc. (AN), Loxo Oncology Inc (LOXO), Amphastar Pharmaceuticals Inc (AMPH), and More
Citadel, the more than $30 billion hedge fund managed by billionaire Ken Griffin, is outperforming the industry and the broader markets so far this year.
13D Filing: Aisling Capital III LP and Loxo Oncology Inc. (LOXO)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d...
13D Filing: OrbiMed Advisors and Loxo Oncology Inc. (LOXO)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d...
Opus Point Partners' AUM, History and Investments
Opus Point Partners was founded by Michael S. Weiss and Dr. Lindsay A. Rosenwald in 2009. Prior to launching Opus Point Partners, Mr. Weiss and Dr.
Amid The Perceived Gloom In The Hedge Fund Universe, This Hedge Fund's Stock Picks Gained 38.8% in Q1
The dismal performance, redemptions and shuttering of some hedge funds have received significant media attention in the past two years.
5 Stocks The Best Performing Hedge Funds Are Piling Into
At Insider Monkey, we track more than 700 of the best hedge funds in the world and have developed various market-beating strategies over the years using the wealth of data we collect from their 13F filings...
One of The Largest Hedge Funds In The World Is Betting On Loxo Oncology Inc. (LOXO)
One of the largest hedge funds in the world is betting on Loxo Oncology Inc. (NASDAQ:LOXO), a biopharmaceuticals company that develops and sells medicine to treat certain types of cancer.
Can Loxo Oncology Inc (LOXO) Candidate Larotrectinib Pass Regulatory Test?
Loxo Oncology Inc (NASDAQ:LOXO) is targeting to file for regulatory approval of its gene mutation cancer drug candidate larotrectinib at the end of next year or early in 2018.
Is Loxo Oncology Inc (LOXO) Worthy of Your Portfolio?
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don...